This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Idexx (IDXX) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Intuitive Surgical, Inc. (ISRG) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Intuitive Surgical, Inc. (ISRG) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Is Most-Watched Stock Intuitive Surgical, Inc. (ISRG) Worth Betting on Now?
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intuitive Surgical, Inc. (ISRG) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $290.39, moving +1.12% from the previous trading session.
3 Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
Alcon (ALC) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Abbott (ABT) EPD Arm Grows, Low Testing Sales Play Spoilsport
by Zacks Equity Research
Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.
Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight report will contain details on how a patient's smoking history may affect their metabolism of certain medications.
Asensus Surgical (ASXC) Q2 Loss Widens, Revenues In Line
by Zacks Equity Research
Asensus Surgical (ASXC) reports a significant increase in total surgical procedures completed utilizing the Senhance System.
National Vision (EYE) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) second-quarter 2023 performance highlights positive comparable store sales growth, retention and recruitment trends.
Here's Why You Should Invest in Alcon (ALC) Stock Now
by Zacks Equity Research
Investors are optimistic about Alcon (ALC) owing to its strength in Surgical and Vision Care franchises and upbeat 2023 guidance.
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina (ILMN) shipped 109 NovaSeq X instruments in the second quarter, boosting its supply capacity to more than 390 instruments for fiscal 2023.
Medtronic (MDT) Rides on Strong Global Growth, New Launches
by Zacks Equity Research
Medtronic (MDT) is gaining from positive sales momentum with the rollout of its differentiated Hugo robotic system in many international markets.
Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances.
Avanos (AVNS) Q2 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Digestive Health segment, its overall second-quarter results reflect soft performances.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and technological investments.
The Zacks Analyst Blog Highlights PepsiCo, Johnson & Johnson, Intuitive Surgical, Kimberly-Clark and Atmos Energy
by Zacks Equity Research
PepsiCo, Johnson & Johnson, Intuitive Surgical, Kimberly-Clark and Atmos Energy are included in this Analyst Blog.
QuidelOrtho (QDEL) Q2 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Despite solid performances by the Labs segment and Other region, QuidelOrtho (QDEL) reports soft overall top-line results in second-quarter 2023.
Masimo (MASI) Q2 Earnings Lag Estimates, Margins Rise
by Zacks Equity Research
Despite strength in Hearables category, Masimo's (MASI) overall second-quarter results reflect soft performances.
Charles River (CRL) Q2 Earnings Top, 2023 View Narrowed
by Zacks Equity Research
Charles River (CRL) registers robust growth in small research models, research model services and the Safety Assessment business.
Insulet (PODD) Q2 Earnings Beat, Sales Growth View Raised
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 gains market share in the second quarter within the diabetes technology market as the only FDA-approved fully disposable, pod-based automated insulin delivery system.
Haemonetics (HAE) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
The robust volume growth and price benefits in the Plasma business drive Haemonetics' (HAE) fiscal first-quarter performance.
QIAGEN (QGEN) Q2 Earnings and Revenues Top, '23 View Slashed
by Zacks Equity Research
QIAGEN (QGEN) surpasses the earnings and revenue outlook in the second quarter of 2023 amid a challenging macro environment.
SmileDirectClub (SDC) Q2 Earnings Miss Estimates, '23 View Up
by Zacks Equity Research
SmileDirectClub (SDC) reports a higher-than-expected loss in the second quarter of 2023.